Cooper Companies Director Kurzius Buys $549,300 in Shares. Is the Eye Care Stock About to Rally?

Lawrence Erik Kurzius, a Director at The Cooper Companies, Inc.(NASDAQ:COO), purchased 10,000 shares of common stock on Sept. 16, 2026, according to a recent SEC Form 4 filing.

Transaction summary

Metric	Value
Transaction value	$549,300
Shares purchased	10,000
Post-transaction shares (directly held)	31,099
Post-transaction value	$1.70 million

Transaction value based on SEC Form 4 weighted average purchase price ($54.93); post-transaction value based on Sept. 16, 2026 market close ($54.61).

Key questions

• What was the total scale of the capital deployment?
  The purchase involved 10,000 shares at $54.93 per share, totaling $549,300 in committed capital.
• How has the director's total equity position changed?
  Lawrence E. Kurzius increased his total direct holdings to 31,099 shares of common stock. This total position was valued at $1.70 million based on the market close on the transaction date.
• What is the recent financial context for the company?
  The Cooper Companies, which operates through its CooperVision and CooperSurgical business units, reported trailing twelve-month revenue of $4.2 billion and net income of $570.3 million.
• At what price level did the insider acquire these shares?
  The shares were purchased at $54.93 per share. This compares to a market closing price of $53.78 as of the Sept. 17, 2026 market close, the day the filing was disclosed.

Company Overview

Metric	Value
Share Price (as of market close 2026-09-17)	$53.78
Market Capitalization	$10.4 billion
Revenue (TTM)	$4.2 billion
Net Income (TTM)	$570.3 million

Company Snapshot

• The Cooper Companies operates two primary business segments: CooperVision, which manufactures and distributes contact lenses, including spherical, toric, multifocal, and specialty myopia management products, and CooperSurgical, which provides surgical and women's health solutions.
• The company generates revenue through the global distribution of medical devices and vision care products to eye care professionals, healthcare providers, and patients, leveraging a diversified product portfolio across contact lens categories and surgical applications.
• The Cooper Companies serves eye care practitioners, ophthalmologists, optometrists, hospitals, and patients worldwide, with a focus on addressing common vision correction needs as well as specialized conditions, including astigmatism, presbyopia, and myopia management.

The Cooper Companies is a global medical device manufacturer with approximately 15,000 employees and a market capitalization of $10.4 billion, generating $4.2 billion in trailing twelve-month (TTM) revenue. The company maintains a competitive position through its dual-segment strategy, combining the scale of its contact lens business with specialized surgical and women's health offerings. Cooper's strategic focus on innovation in vision correction and myopia management, coupled with its established distribution network, positions it as a significant player in the global ophthalmic medical device market.

What this transaction means for investors

There are many reasons an insider may sell a company's shares. One reason could be the need to raise cash to fund a large personal expense. Another reason could be for a reasonable portfolio diversification unrelated to their outlook for the company. A third reason could be what investors fear most: a bearish outlook on the company's future.

However, there is only one reason an insider buys stock: they believe the share price is going up!

By that investor's rule of thumb, Kurzius's purchase of Cooper Companies's shares is inherently bullish.

On top of that, studies show that, more often than not, an insider purchase predicts a higher share price 30 days later.

Kurzius is an independent director of the company. He also serves as CEO of McCormick & Co (NYSE:MCK), so he knows what the market is looking for in a publicly traded company. It's another bullish signal here.

Cooper was considering spinning off or selling its surgical unit, but opted to keep it in-house. That's a sign that they believe there is more value to owning the business ahead. For the current fourth quarter of its fiscal year, the company expects consolidated revenue of $1.057 billion to $1.08 billion, representing organic growth of 0% to 2%. That's not great, but management believes it sets the stage for a better 2027.

Insider buying, like Kurzius's, suggests a belief in the company's long-term growth and profitability for shareholders.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool recommends McKesson. The Motley Fool has a disclosure policy.